静脉输入与口服"L-ornithine-L-aspartate"在明显的肝脑病变:一个随机比较研究
Ashok Jhajharia1,2, Shashank Singh3, Sangeeta Jana3
1Department of Gastroenterology, SMS Medical College & Hospital, Jaipur, Rajasthan, 302004, India. drashokjhajharia@gmail.com.
Scientific reports
|May 24, 2024
概括
在慢性肝病患者中,L-ornithine-L-aspartate (LOLA) 有效治疗明显的肝脑病变 (OHE). 静脉注射和口服LOLA都显示了HE等级和氨水平的显著改善.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床药理学 临床药理学
背景情况:
- 肝性脑病变 (HE) 显著影响慢性肝病 (CLD) 的患者.
- 目前的治疗方法,如乳糖和利法西明有局限性,推动寻找更优质的药物.
- 甲酸L-甲酸L-酸盐 (LOLA) 是对HE的潜在治疗剂.
研究的目的:
- 为了比较静脉注射 (IV) LOLA与口服LOLA在患有CLD和公开HE (OHE) 的患者中的疗效.
- 评估LOLA对HE等级改善和血清氨水平的影响.
- 为了评估HE等级和氨水平之间的相关性,使用不同的LOLA给药途径.
主要方法:
- 一项随机对照试验 (RCT) 涉及40名患有OHE的CLD患者.
- 患者被随机分配,以1:1的比例接受IVLOLA或口服LOLA.
- 从第1天到第5天,每天监测HE分级和血清氨水平.
主要成果:
- 在IV和口服LOLA组之间,氨水平的平均降低没有显著差异 (p=0.511).
- 输液和口服LOLA都显示了从第1天到第5天血清氨水平的显著降低 (p<0.001).
- 在两个治疗组中,在HE级和氨水平之间观察到正相关性.
结论:
- 无论用哪种方式 (IV或口服),LOLA都能有效治疗明显的肝脑病变.
- 该研究提供了LOLA作为CLD患者中HE可行的治疗选择的证据.
- 进一步的研究可能会探索LOLA在HE管理中的最佳剂量和长期疗效.
更多相关视频
04:28Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
Published on: March 23, 2016
12.7K
12:27Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
Published on: May 7, 2015
16.5K
相关概念视频
Drug Delivery: Parenteral Route
502
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
502
Anticholinesterase Agents: Poisoning and Treatment
848
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
848
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.1K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
